Device Trial Radar · NCT05902793
Evaluating the Efficacy and Safety of the VERAFLO™ Dressing Kit for Wound Bed Preparation in Open Wounds
Last checked: Nov 20, 2026Latest source record: Mar 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
170
Actual
Start
Aug 4, 2020
Primary completion
Sep 18, 2023
Study completion Sep 19, 2023
Sponsor
- Lead sponsor
- KCI USA, IncNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jun 15, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives are to evaluate the efficacy and safety of the V.A.C. VERAFLO™ Dressing Kit for wound bed preparation in open wounds with extensive soft tissue damage in this trial.
Conditions
- Wound Healing
Interventions
Investigational device: V.A.C. VERAFLO™ Dressing KitDevice
Up to 170 subjects who meet the eligibility criteria will be randomized to the investigational group or control group at the ratio 1:1. Subjects will only be enrolled following definitive surgical debridement (if serial debridement performed) of the target wound. The target wound for each subject in both groups will be treated for up to 14 days or until deemed ready for closure by the investigator (whichever occurs first). The planned study period consists of the following visits: Screening (Day -3 to 0), Day of randomization (Day0), Dressing change visit(s), End of treatment visit. Following study treatment, the wound may be treated with any standard therapy selected by the physician, and then accepted secondary intervention for wound closure according to the wound bed preparation situation.
Comparator device: Negative pressure wound drainage materialDevice
Up to 170 subjects who meet the eligibility criteria will be randomized to the investigational group or control group at the ratio 1:1. Subjects will only be enrolled following definitive surgical debridement (if serial debridement performed) of the target wound. The target wound for each subject in both groups will be treated for up to 14 days or until deemed ready for closure by the investigator (whichever occurs first). The planned study period consists of the following visits: Screening (Day -3 to 0), Day of randomization (Day0), Dressing change visit(s), End of treatment visit. Following study treatment, the wound may be treated with any standard therapy selected by the physician, and then accepted secondary intervention for wound closure according to the wound bed preparation situation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Wound Volume Reduction Rate (Unit: %)Time frame: over 14 days or until deemed ready for closure by investigator (whichever occurred first)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Anhui Provincial Hospital
Hefei, Anhui, China
Foshan Hospital of TCM
Foshan, Guangdong, China
Xi'an Honghui Hospital
Xi’an, Shanxi, China
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.